With its Alzheimer's drug in turmoil, Biogen eyes a list of potential acquisitions – STAT
Business News
- With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions STAT
- Biogen seeks dialogue with U.S. CMS about Alzheimer’s drug coverage decision Reuters
- Analysts say Medicare decision could spell the demise of Biogen’s Alzheimer’s drug BetaBoston
- With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment STAT
- Biogen rebounds amid comments on M&A prospects Seeking Alpha
- View Full Coverage on Google News
Source: Business News